Welcome back to Season 4! This episode of Novel Targets was recorded at the 2018 annual meeting of the American Association for Cancer Research (AACR) in Chicago. This time around, we’re talking about cancer immunotherapy clinical practice, pitfalls in trial design/interpretation, emerging biomarkers, and possibilities for future cures in some patients.

Professor Tom Powles

Tom Powles (Barts Cancer Centre) is a regular on the podcast. He previously featured in Episode 7 , where he talked about some of his experience with the checkpoint inhibitor, atezolizumab, in bladder cancer.